Lilly Endowment Inc Portfolio Concentration: 100% Eli Lilly Holdings

Lilly Endowment Inc, a significant investor, has a portfolio that is entirely concentrated in a single holding as of September 30, 2026. This high level of concentration is evident from the data, which shows that all 100% of the portfolio's value is invested in Eli Lilly and Company (LLY). The institution's holdings in this pharmaceutical giant have seen a slight decrease in both share count and value compared to the previous period.

The sole position in the portfolio belongs to Eli Lilly and Company (LLY), a major player in the pharmaceutical industry. The total stock value invested by Lilly Endowment Inc is substantial, totaling $104.2 billion. This indicates a significant trust in the company's potential, though it also highlights the substantial risk associated with such a concentrated position.

From the top holdings data, we see that Eli Lilly and Company is the only stock held, accounting for the entire portfolio value. The sector allocation data confirms that the entire $104.2 billion is allocated to the Healthcare sector, specifically within the Pharmaceuticals sub-sector. This complete allocation means there is no diversification across different industries or companies, making the portfolio highly susceptible to the performance and risks specific to Eli Lilly and the broader pharmaceutical industry.

The portfolio's holdings show a slight reduction, with a decrease of 310,000 shares and a value decrease of approximately 0.34%. While the absolute change might not be dramatic, the fact that it's the only holding means any percentage change in the stock price will have a magnified impact on the overall portfolio value. Investors analyzing Lilly Endowment Inc's investment strategy should be aware of this total reliance on one stock.

Given the 100% allocation to Eli Lilly and Company, the portfolio's performance is intrinsically tied to the success of this single stock. This level of concentration is characteristic of a concentrated portfolio strategy, which can offer potentially higher returns but also carries significantly higher risk compared to more diversified portfolios. The portfolio's top holdings and sector allocation data both point to a strategy focused entirely on the pharmaceutical sector, specifically on the performance of Eli Lilly.

The data indicates that Lilly Endowment Inc has chosen to allocate its entire investment to Eli Lilly and Company. This decision reflects a strong conviction in the company's prospects, but it also means that the institution has no exposure to other sectors or companies. The total shares held are 90,066,978, representing a massive position in the market.

For a comprehensive view of Lilly Endowment Inc's investment profile, including this concentrated position, one can refer to the detailed portfolio data. Similarly, for more information on Eli Lilly and Company's stock, the LLY profile provides valuable insights into its market position and performance.